WP
ALXN

WealthSource Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

WealthSource Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,955
Closed -$353K – 351
2017
Q4 		$353K Sell
2,955
-75
-2% -$9.13K 0.11% 175
2017
Q3 		$425K Buy
3,030
+28
+0.9% +$3.8K 0.14% 158
2017
Q2 		$365K Buy
3,002
+126
+4% +$14.7K 0.12% 168
2017
Q1 		$349K Buy
+2,876
New +$371K 0.13% 174

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WealthSource Partners's ALXN Position: Q1 2018 in Review

WealthSource Partners sold out of Alexion Pharmaceuticals (ALXN) in Q1 2018, closing a stake of 2,955 shares — an estimated $353K sold.

WealthSource Partners first reported a position in ALXN in Q1 2017 and held it in 4 quarters. The position peaked at $425K in Q3 2017. 596 funds tracked by Wall St. Rank hold ALXN as of Q1 2018.

  • WealthSource Partners reported no remaining Alexion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • WealthSource Partners sold 2,955 Alexion Pharmaceuticals shares in Q1 2018, an estimated $353K.
  • WealthSource Partners first reported a position in Alexion Pharmaceuticals in Q1 2017 and held it in 4 quarters.
  • WealthSource Partners's Alexion Pharmaceuticals position peaked at $425K in Q3 2017.
  • 596 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2018.

Based on WealthSource Partners's 13F filing for Q1 2018, filed 16 Apr 2018.